Disclosed herein are methods of using a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of psychosis or psychotic symptoms in an individual comprising administering to said individual in need thereof a therapeutically effective amount of said 5-HT2A serotonin receptor inverse agonist. Further disclosed herein are methods of using a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of Parkinson's disease psychosis in an individual comprising administering to said individual in need thereof a therapecutically effective amount of said 5-HT2A serotonin receptor inverse agonist.
USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS